Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Hepatitis B Virus
Research on hepatitis B virus discussed by C.W. Ho and co-researchers
June 18th, 2008
According to recent research from Serdang, Malaysia, "HBcAg (hepatitis B core antigen) is a nanoplex bioproduct that has a great potential in the development of therapeutic drugs and vaccines. In the present study, a continuous-flow bead milling for the disruption of Escherichia coli was optimized and a direct recovery protocol to isolate the recombinant HBcAg from the unclarified E. coli disruptate was developed." "The optimal condition for continuous-flow bead milling for the release of HBcAg from E. coli was achieved at a feed flow rate of 15 litres/h, biomass concentration of 10% [ww/v (wet weight/vol.)] and impeller tip speed of 14 m/s. The sucrose-density-gradient...
Source: Vaccine Weekly (2008-06-18)
|
